Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 776 - 800 of 15325 in total

Interferon alfa-n1

Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Torasemide

Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved

Sulesomab

Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Inflammation and Infection Detection …

Metolazone

A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Approved
Matched Description: … It also tends to lower blood pressure and increase potassium loss. …
Matched Categories: … Genito Urinary System and Sex Hormones ... metolazone and potassium-sparing agents ... Gynecological Antiinfectives and Antiseptics ... Low-Ceiling Diuretics and Potassium-Sparing Agents …

Relugolix

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …

Tezacaftor

Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … consequently abnormal fluid and ion transport across cell membranes. ... [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …

Acetohexamide

A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Cenegermin

Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and ... L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and ... Cenegermin also received Orphan Drug designation, which provides incentives to assist and encourage the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Rozanolixizumab

Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November 2020. ... Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. ... [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Human interferon beta

Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and ... [L12081] Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Crizanlizumab

Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … It was developed by Novartis and was granted FDA approval on November 15, 2019. ... L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and ... Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Becaplermin

Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together...
Approved
Investigational
Matched Description: … Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins ... Preparations for Treatment of Wounds and Ulcers …

Cetuximab

Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible...
Approved
Matched Description: … neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with ... EGFR overexpression has been linked to more advanced disease and poor prognosis. ... cells; it is responsible for regulating epithelial tissue development and homeostasis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Casein

Casein allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Fluids and Secretions ... Diet, Food, and Nutrition ... Amino Acids, Peptides, and Proteins …

Plasminogen

Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond...
Approved
Matched Description: … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Terconazole

Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a triazole ketal derivative. Terconazole was initially approved by the FDA in 1987.[FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels...
Approved
Matched Description: … [FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels ... of safety, efficacy, and tolerability in clinical trials. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Troglitazone

Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … It was superseded by [pioglitazone] and [rosiglitazone]. …
Matched Categories: … Alimentary Tract and Metabolism …

Miltefosine

Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of ... It can be administered topically or orally and is only indicated in patients aged 12 years or older. ... first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Tafamidis

Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Iupac: … 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid …
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Sacituzumab govitecan

Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … Commission and Health Canada respectively. ... [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed ... [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Antithymocyte immunoglobulin (rabbit)

Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of...
Approved
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Antilymphocyte immunoglobulin (horse)

Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that...
Approved
Investigational
Matched Description: … system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and ... currently indicated for the suppression of the immune system to prevent renal transplant rejection and ... Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Corticorelin ovine triflutate

Corticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic form of the peptide human corticotropin-releasing hormone (hCRH), a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the pituitary...
Approved
Matched Description: … Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the ... If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed ... However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Diiodohydroxyquinoline

Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Description: … Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Displaying drugs 776 - 800 of 15325 in total